Research news
Management of autosomal dominant polycystic kidney disease in the era of disease-modifying treatment options
February 2022
Design and basic characteristics of a national patient-powered registry in ADPKD
May 2022
Health Disparities in ADPKD in the United States
June 2022
Changing Health Disparities in ADPKD: a patient perspective
June 2022
Comparison of a pooled tolvaptan cohort to a pooled control cohort with ADPKD supports longer-term treatment effects of tolvaptan
May 2022
Insights into a tethered agonist-mediated activation mechanism of PC1 CTF signaling – how they inform future rational drug design targeting PC1
May 2022
Diagnosis and risk factors for intracranial aneurysms in ADPKD: a cross-sectional study from the Genkyst cohort
February 2022
Asymptomatic pyuria as a prognostic biomarker: associated with kidney failure and faster kidney function decline irrespective of the ADPKD gene, cystic burden, and cystic growth
March 2022
Kidney epithelial cells are active mechano-biological fluid pumps
April 2022
A single cell transcriptomic and epigenomic landscape of ADPKD
December 2021
A special issue on Cell Signaling in PKD, led by Drs. Albert C.M. Ong and Vicente E. Torres, and consisting of 30 papers from many respected members of the PKD research community.
July 2020
Cellular signaling in PKD foreword: dedicated to the memory of Dr. Jared James Grantham (1936–2016); without his vision, achievements and impact on countless collaborators and disciples, the field of Polycystic Kidney Disease would not be where it is today.
A study demonstrates the therapeutic feasibility of caloric restriction in ADPKD, with potential efficacy benefits driven by weight loss
January 2022
Linking a ciliary structural protein to the ADPKD spectrum – PKD1 variants could modify the IFT140 phenotype.
January 2022
Immune Cell Atlas Reveals the Involvement of Adaptive Immune Cells in Injury-Mediated Cyst Progression in Mice
February 2022
Insights Into the Molecular Mechanisms of Polycystic Kidney Diseases
September 2021
A Post Hoc Analysis of Clinical Trial Outcomes With Tolvaptan in ADPKD
April 2021
A substantial proportion of adolescents with ADPKD experience physical, social, and emotional impacts from their disease
January 2022
An updated algorithm to guide patient selection for treatment with tolvaptan and practical advice for its use
November 2021
Selective targeting of cyst cell proliferation is an effective means of slowing ADPKD progression caused by inactivation of Pkd1
November 2021
Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease
November 2021
The importance of local and systemic metabolism in ADPKD: current evidence for dietary interventions to slow disease progression and improve quality of life
November 2021
A possible association of a PKD2 mutation with an increased hazard of cardiac hospitalization as compared with PKD1
October 2021
Phenotypic features of ADPKD may be reversible -the kidney has an unexpected capacity for plasticity controlled at least in part by ADPKD gene function
October 2021
New insights into the normal function of PC2 as a ubiquitous stress-sensitive protein
January 2020
Results from the metformin feasibility study at University of Colorado Denver
August 2021
Inhibition of exosome biogenesis/release significantly delays cyst growth in aggressive and milder ADPKD mouse models
July 2021
A review summarizing current knowledge about the regulatory mechanism of ferroptosis and its association with several pathways, including iron, lipid, and cysteine metabolism
February 2021
Real-world utilization patterns of imaging scans in patients diagnosed with ADPKD
May 2021
Expanding the understanding of genotype-phenotype correlations in pediatric ARPKD
April 2021
Long-term treatment with tolvaptan gradually lowered blood pressure compared with placebo in clinical trials
April 2021
An analysis of the HALT-PKD data: pain and obesity in ADPKD
April 2021
Estimated total annual costs attributed to ADPKD estimated at $51,970 to $68,091 per patient
February 2020
Development of an ADPKD-specific pain assessment tool (APAT) to facilitate pain research
February 2021
Baseline urinary metabolic biomarkers associated with disease severity in TAME-PKD cohort
March 2021
A review assessing the risk of disease progression in ADPKD and identifying patients who would benefit from long-term therapy of disease-modifying agents
March 2021
A review of aspects of early manifestations in ARPKD and its clincial management with a special focus on kidney disease
February 2021
New conclusions on patients with protein-truncating PKD1 Mutations and mild disease
February 2021
A practical guide for the diagnostic and therapeutic management of an “acute abdominal pain with fever” in patients with ADPKD
February 2021
CDK7 as a novel therapeutic option: how super-enhancers play a critical role in ADPKD
July 2020
Urine-to-plasma urea ratio, calculated from routine laboratory measurements, predicts disease progression in ADPKD
January 2021
A proof-of-concept for application of the combination of curcumin and ginkgolide B in inhibiting cystogenesis in ADPKD
January 2021
Using the Mayo Classification to evaluate the need for nephrectomy in ADPKD patients
December 2020
Predicting ADPKD outcomes using serum bicarbonate: a potential new prognostic model
December 2020
Refuting the hypothesis that Ca2+ occupancy of the polycytsin-2 intracellular EF hand is responsible for channel regulation, and if disrupted, results in ADPKD
October 2020
Cystogenesis and inflammation may be associated with endothelial dysfunction; ADPKD patients observed to have higher copeptin, NLRP3, and suPAR levels than controls
October 2020
Prospective observations of a cohort of 73 individuals with molecularly confirmed ARPKD-congenital hepatic fibrosis
September 2020
A review of the advances and application of kidney organoids in regenerative medicine and as developmental, toxicity, and disease models
October 2020
Fibrocystin’s role in controlling STAT3 signalling in ARPKD
October 2020
Five novel GANAB variants found to be associated with PLD in both ADPKD and ADPLD patients
October 2020
Loss of Cdk1 significantly slows kidney cyst growth with Pkd1 inactivation
October 2020
A focus group study on presymptomatic testing and decision-making challenges
October 2020
An editorial on sclerotherapy outcomes in ADPKD patients for treatment of pain
October 2019
Hedgehod signaling and the role of fibrocystin in the abnormal vascular phenotype of PKD
October 2020
NIDDK Director, Robert Starr, discusses the promotion of innovative research in nephrology
August 2020
The role of excessive salt intake and vasopressin in promotion of cyst growth
October 2020
Laparoscopic bilateral nephrectomy at the time of kidney transplantation appears safe and feasible for ADPKD patients with living donors
September 2020
Development and validation of a fully automated approach for performing semantic segmentation of kidney cysts in MR images ADPKD patients
September 2020
New conclusions about PKHD1 and polycystic liver disease
September 2020
A new therapeutic concept using the FDA-approved drugs niclosamide and benzbromarone, and a TMEM16A-specific inhibitor in ADPKD mice
August 2020
Metabolic changes in PKD and their modulation as a potential target of systemic treatment
August 2020
SONG-PKD report on core outcomes sets for ADPKD trials
August 2020
A Patient Perspective on Genetic Testing for ADPKD
August 2020
Robotic ultrasound provides a rapid and accurate approach for noninvasively evaluating PKD in rodent models
August 2020
Measuring liver disease severity in ARPKD using magnetic resonance elastography
August 2020
The value of imaging, genotypic, and combined data to identify rapidly progressive ADPKD patients
August 2020
Qinzhe Wang, MS, PhD (University of Utah) awarded the Jared J. Grantham Research Fellowship
July 2020
Upregulated SEMA3C may contribute to survival of polycystic kidney epithelial cells
July 2020
Genetic reduction of cilium-length by targeting intraflagellar transport 88 protein impedes kidney and liver cysts formation
June 2020
Niacinamide well-tolerated in ADPKD patients, but no efficacy observed
June 2020
Genetic reduction of cilium length may offer novel therapeutic approaches for ADPKD
June 2020
Overview of in vivo and in vitro models for ADPKD
June 2020
More from HALT-PKD: KIM-1 and ADPKD progression
June 2020
MRI-based kidney T1 and T2 mapping as a non-invasive assessment of ARPKD progression
April 2020
An expanded imaging classification model for ADPKD
June 2020
A report on heathcare cost burden in ADPKD
April 2020
Identification of critically important consensus-based core outcome domains to be reported in trials
April 2020
Role of chemokines, innate and adaptive immunity in PKD
April 2020
A review of contributing factors of cardiovascular dysfunction in ADPKD
April 2020
The molecular impact of variants found in the TOP domain of polycystin-2
May 2020
Impaired mitochondrial structure and function play a role in PKD progression
April 2020
A review of outcomes reported in randomized trials conducted in patients with PKD
March 2020
Urinary exosomal miRNAs could serve as novel biomarkers of disease progression
March 2020
DNAJB11 mutations as described by atypical clinical presentations of ADPKD
March 2020
ADPKD’s economic burden is predominantly observed in direct health care costs
February 2020
National strategies needed to address racial and ethnic disparities in predialysis nephrology care
August 2020
Development of a high-throughput screening platform of cancer drugs in a quest to repurpose them for ADPKD
March 2020
Understanding the interplay between dysregulation of cellular metabolism and cystogenesis is likely to uncover pathways that can be directly modulated to treat PKD
September 2019
A review of ciliary dysfunction in cystic disease and the questions that remain
December 2019
A review and discussion of the therapeutic potential of metabolic reprogramming strategies in ADPKD
February 2020
Tubular secretion could be impaired in ADPKD independent of GFR
January 2020
Dietary phosphate restriction slows renal cyst growth and fibrosis in Pcy/pcy mouse model of PKD
January 2020
Patient engagement in research design improves feasibility, acceptability, rigor and relevance
March 2019
New mutation associated with ADPKD found on ALG9 gene
November 2019
Utilizing mosaicism to provide informed prognostic information and fully characterize ADPKD populations
February 2020
Cystic cells in PKD may be metabolically inflexible and could be exploited by dietary interventions or supplementation
December 2019
Meta-analysis demonstrates that GFR slope might be a viable surrogate endpoint in clinical trials for CKD
September 2019 
FDA Removes Partial Clinical Hold for Multiple Ascending Dose Study of RGLS4326
December 2019
Addressing the Need for Clinical Trial End Points in Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC)
April 2019
FDA-approved cystic fibrosis drug, VX-809, may have potential utility for treating patients with ADPKD
December 2019
A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan
October 2018
Ultrasound elastography is a useful noninvasive biomarker to detect and quantify liver fibrosis and portal hypertension in children with ARPKD
June 2019
PKD progression may be accelerated by commonly occurring renal crystal deposition that could be therapeutically controlled by relatively simple measures
July 2019
Metabolomics in ADPKD: how plasma metabolites and lipids are associated with kidney function and kidney volume in hypertensive patients
February 2019
A recent analysis on how race/ ethnicity affects progression and initiation of dialysis in ADPKD patients in the US
February 2019
How do cysts grow in ADPKD and how is it related to the gene?
June 2019
Get the latest information on treating PKD.
More information
For additional research information contact us!
Email: research@pkdcure.org
Phone: (800) 753-2873
Page last revised May 24, 2022